证券代码：688108 证券简称：赛诺医疗 公告编号：2025-050 赛诺医疗科学技术股份有限公司关于召开子公司 产品注册申请未获批准的投资者交流会通知公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、交流会类型 赛诺医疗科学技术股份股份有限公司（以下简称"赛诺医疗"或"公司"） 于 2025 年 10 月 30 日在上海证券交易所网站（http://www.sse.com.cn）上披露 了《赛诺医疗科学技术股份有限公司关于子公司产品注册申请未获国家药监局批 准的自愿性披露公告》。 为加强与投资者的深入交流，便于广大投资者更全面深入地了解本次子公司 产品注册申请未获国家药监局批准的情况以及公司后续经营发展情况，在上海证 券交易所的支持下，公司计划于 2025 年 10 月 30 日 15:30-17:00 在上证路演中 心（网址：https://roadshow.sseinfo.com/）以直播+网络互动的方式举行关于 子公司产品注册申请未获批准的投资者交流会，与广大投资者进行充分交流，解 答投 ...

Core Viewpoint - Sino Medical (688108) announced that its subsidiary, Sino Shenchang Medical Technology Co., Ltd., received a notification from the National Medical Products Administration (NMPA) stating that the registration application for its COMETIU self-expanding intracranial drug-coated stent system was not approved [1] Group 1 - The COMETIU stent's registration application was publicly disclosed as not approved by the NMPA on October 28 [1] - The company stated that the lack of domestic registration approval for the COMETIU stent will not have a short-term impact on its production and operations [1] - The company will continuously assess the long-term impact of the registration denial and will proceed with clinical, registration, and commercialization processes for the COMETIU stent in domestic, European, American, and global markets [1]

Core Viewpoint - Sino Medical announced that its subsidiary, Sino Shenchang, received a "medical device registration not approved" notice from the National Medical Products Administration for its COMETIU self-expanding intracranial drug-coated stent system, which was not approved for domestic registration. However, the product is making positive progress overseas, having passed the EU MDR on-site quality system audit and is in the final stage of technical review. It has also received breakthrough medical device designation from the FDA, allowing it to directly conduct pivotal confirmatory clinical studies. The company will advance its global commercialization, and the domestic registration denial will not have a short-term impact on production and operations [1]. Summary by Category Product Development - The COMETIU self-expanding intracranial drug-coated stent system did not receive domestic registration approval from the National Medical Products Administration [1] - The product has successfully passed the EU MDR on-site quality system audit and is in the final stage of technical review [1] - The product has received breakthrough medical device designation from the FDA, enabling the company to conduct pivotal confirmatory clinical studies directly [1] Business Impact - The company plans to push forward with global commercialization of the product [1] - The denial of domestic registration is not expected to impact production and operations in the short term [1]

Core Viewpoint - The company, Sainuo Medical, is currently in the registration process for its intracranial drug-eluting stent and has not yet received the review results from the regulatory agency [1] Group 1 - The company responded to investor inquiries on October 28 regarding the status of its intracranial drug-eluting stent [1] - The company will disclose the review results in accordance with legal regulations and requirements from regulatory agencies once they are received [1] - Investors are advised to pay attention to subsequent announcements on the Shanghai Stock Exchange website [1]

Core Insights - The medical device sector experienced a slight increase of 0.37% on October 24, with Mai Lande leading the gains [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Medical Device Sector Performance - Top gainers included: - Mai Lande (688273) with a closing price of 41.92, up 6.31%, trading volume of 29,300 hands, and a transaction value of 121 million yuan [1] - Xiangyu Medical (688626) at 53.21, up 6.10%, with a trading volume of 41,100 hands and a transaction value of 216 million yuan [1] - Xiangsheng Medical (688358) at 35.27, up 4.75%, with a trading volume of 38,400 hands and a transaction value of 136 million yuan [1] - Other notable gainers included: - Aohua Endoscopy (688212) at 50.59, up 4.74%, with a transaction value of 225 million yuan [1] - Weisi Medical (688580) at 49.10, up 4.71%, with a transaction value of approximately 99.8 million yuan [1] Decliners in Medical Device Sector - Notable decliners included: - Chenguang Medical (920300) at 17.51, down 8.80%, with a trading volume of 124,000 hands [2] - Toukeng Life (300642) at 22.95, down 5.40%, with a trading volume of 175,700 hands [2] - Haitai New Light (688677) at 48.50, down 5.05%, with a trading volume of 38,800 hands [2] - Other significant decliners included: - Sino Medical (688108) at 28.00, down 4.73%, with a trading volume of 263,700 hands [2] - Tianchen Medical (688013) at 55.66, down 3.98%, with a trading volume of 19,200 hands [2] Capital Flow in Medical Device Sector - The medical device sector saw a net outflow of 654 million yuan from major funds, while retail investors contributed a net inflow of 455 million yuan [2]

Market Overview - The Shanghai Composite Index rose by 0.22% on October 23, with 21 out of 28 sectors experiencing gains. The top-performing sectors were coal and oil & petrochemicals, with increases of 1.75% and 1.53% respectively. Conversely, the telecommunications and real estate sectors saw declines of 1.51% and 0.99% respectively [1] Capital Flow Analysis - The main capital flow showed a net outflow of 33.733 billion yuan across the two markets. Six sectors experienced net inflows, with the coal sector leading at a net inflow of 1.465 billion yuan, followed by the media sector with a net inflow of 362 million yuan [1] - A total of 25 sectors faced net outflows, with the electronics sector experiencing the largest outflow of 5.435 billion yuan, followed by the machinery equipment sector with an outflow of 4.999 billion yuan. Other sectors with significant outflows included pharmaceuticals, telecommunications, and electrical equipment [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector declined by 0.60%, with a net outflow of 4.627 billion yuan. Out of 475 stocks in this sector, 183 stocks rose, 4 stocks hit the daily limit up, and 274 stocks fell [2] - Within the sector, 121 stocks saw net inflows, with five stocks receiving over 30 million yuan in net inflows. The top stock for net inflow was Jianfa Zhixin, with an inflow of 123 million yuan, followed by Sainuo Medical and Mindray Medical with inflows of 121 million yuan and 60.069 million yuan respectively [2] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Jianfa Zhixin: +20.00% with a turnover rate of 59.71% and a net inflow of 122.929 million yuan - Sainuo Medical: +4.74% with a turnover rate of 6.99% and a net inflow of 121.228 million yuan - Mindray Medical: +0.73% with a turnover rate of 0.41% and a net inflow of 60.069 million yuan [2] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - Shutaishen: -7.52% with a net outflow of 195.891 million yuan - Zhendai Medical: +2.51% with a net outflow of 185.422 million yuan - Yatai Pharmaceutical: -5.58% with a net outflow of 164.905 million yuan [3]

Core Insights - The medical device sector experienced a slight increase of 0.01% on October 23, with Chen Guang Medical leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index also rose by 0.22% to 13025.45 [1] Medical Device Sector Performance - Chen Guang Medical (code: 920300) saw a significant rise of 16.01%, closing at 19.20 with a trading volume of 126,000 shares and a transaction value of 230 million [1] - Other notable gainers included Shuoshi Biology (code: 6628899) with a 7.07% increase, closing at 75.38, and Kangwei Century (code: 688426) which rose by 5.17% to 28.70 [1] - Conversely, the sector also had some decliners, with Toukeng Life (code: 300642) dropping by 6.19% to 24.26, and Rejing Biology (code: 688068) decreasing by 4.07% to 165.15 [2] Capital Flow Analysis - The medical device sector experienced a net outflow of 542 million from institutional investors, while retail investors saw a net inflow of 373 million [2] - Notable net inflows from retail investors were observed in several companies, including Sainuo Medical (code: 688108) with a net inflow of 1.33 billion [3] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors remain active in the market [2][3]

Core Insights - Sino Medical (688108) closed at 28.19 CNY on October 17, 2025, up 1.92% from 27.66 CNY the previous week, with a market cap of 11.728 billion CNY [1] - The stock reached a high of 31.45 CNY and a low of 26.08 CNY during the week [1] Trading Information Summary - On October 13, 2025, Sino Medical recorded a large transaction amounting to 4.6788 million CNY [2] Shareholder Changes - Shareholder Guo Yanchao reduced his holdings by 168,000 shares on October 13, 2025, representing 0.0404% of the total share capital, at a price of 27.85 CNY per share, totaling 4.6788 million CNY. His shareholding decreased from 5.01% to 4.97% [3][5] - Guo Yanchao had previously reduced his holdings by 1.93 million shares from July 21 to July 22, 2025, accounting for 0.46% of the total share capital [3] Company Announcement Summary - Guo Yanchao's reduction was due to personal financial needs, and it will not affect the control of the company [4] - Sun Jianhua signed an agreement to terminate the concerted action relationship with several parties on October 17, 2025, reducing his controlled shareholding from 24.3641% to 19.3156%, with the number of shares controlled decreasing from 101,426,524 to 80,370,369 [4][5]

证券代码：688108 证券简称：赛诺医疗 赛诺医疗科学技术股份有限公司 简式权益变动报告书 信息披露义务人：孙箭华 住 址：北京市海淀区高梁桥斜街13号院**** 通讯地址：北京市海淀区高梁桥斜街59号中坤大厦701-707 股份变动性质：控制的股份减少（解除一致行动） 签署日期：2025年10月17日 上市公司：赛诺医疗科学技术股份有限公司 上市地点：上海证券交易所 股票简称：赛诺医疗 股票代码：688108 声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办 法》《公开发行证券的公司信息披露内容与格式准则第15号--权益变动报告书》及相关的法 律、法规和规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违反其章程或 内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》等的规定，本报告书已 全面披露信息披露义务人在赛诺医疗科学技术股份有限公司中拥有权益的股份变动情况。 截至本报告书签署日，除本报告书披露的持股信息外，信息披露义务人没有通过任何其 他方式增加或减少其在赛诺医疗科学技术股份有限公司中拥有权 ...

赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）于近日收 到公司实际控制人孙箭华先生发来的《简式权益变动报告书》，因与公司股东天津阳 光德业企业管理合伙企业（有限合伙）（以下简称"阳光德业"）、天津阳光广业企业 管理合伙企业（有限合伙）（以下简称"阳光广业"）、天津阳光永业企业管理合伙企 业（有限合伙）（以下简称"阳光永业"）、天津阳光福业企业管理合伙企业（有限合 伙）（以下简称"阳光福业"）签署了《一致行动解除协议》，导致其控制的公司权益 发生变动。现将孙箭华先生有关权益变动情况公告下： 姓名 孙箭华 身份证号 110108************ 关联自然人性别 男 关联自然人国籍 中国 关联自然人通讯地址 北京市海淀区高梁桥斜街 13 号院**** 一、信息披露义务人基本情况 本次权益变动属于解除一致行动人触发的权益减少，不涉及股份增减持、要约收购 等事项。 本次解除一致行动导致的权益变动完成后，信息披露义务人控制上市公司股份的数 量减少至 80,370,369 股，占上市公司股份总数的 19.3156%。信息披露义务人直接 及间接持有的上市公司股份未发生变化。 本次解除一致行动导致的权益 ...